Premium
Renal function one year after switching from Sandimmun® to Neoral®
Author(s) -
Seydoux Charles,
Stumpe Frank,
Hurni Michel,
Ruchat Patrick,
Fischer Adam,
Mueller Xavier,
Von Segesser Ludwig,
Goy JeanJacques
Publication year - 1999
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.1999.130604.x
Subject(s) - medicine , renal function , urology , creatinine , bioavailability , renal replacement therapy , pharmacokinetics , kidney , surgery , pharmacology
Background. The replacement of Sandimmun ® by Neoral ® in 1995 was thought to cause subsequent renal function deterioration due to the better bioavailability of the new drug. We prospectively analyzed the effect of a dose‐to‐dose drug replacement on renal function over 12 months.Methods and results. The renal function of 47 consecutive heart transplanted patients was prospectively evaluated before (T0), at 1 (T1), 3 (T3), and 12 (T12) months after drug replacement. Mean serum creatinine was not significantly different at T0 and T12 (142±55 and 154±60 μmol/L, p=0.1). We were able to reduce cyclosporine total and weight‐indexed doses by, respectively, 11% and 14% between T0 and T12 (274±86 to 244±72 mg/d, p=0.0003; and 3.7±1.4 to 3.2±1.2 mg/kg/d, respectively, p=0.0005).Conclusions. This study demonstrates that the dose‐to‐dose replacement of Sandimmun by Neoral is feasible, with no direct influence on renal function over a 1‐yr follow‐up.